Mylan Settles EpiPen Price-Gouging Class Suit for $264 Million

EpiPen buyers leading a class action against various Mylan defendants are seeking Kansas federal court approval for a $264 million settlement that, together with a previous settlement with defendant Pfizer, brings their total recovery to $609 million.

The agreement is substantially similar to the court-approved Pfizer Inc. settlement, the group told the U.S. District Court for the District of Kansas on Monday.

It provides that Mylan NV initially will deposit $5 million into an escrow account, with the rest to be deposited by July 1 or five days before the fairness hearing, whichever occurs first, the group said. The settlement ...